29004-73-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-3-methanol-1H-pyrazol [1R-(1,2,5)] is used as a reactant for the preparation of 3,5-disubstituted N-unsubstituted pyrazoles from protected alkynols. These pyrazole derivatives are valuable in the development of new pharmaceutical compounds, as they can exhibit a range of biological activities, including anti-inflammatory, anti-cancer, and anti-microbial properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-Methyl-3-methanol-1H-pyrazol [1R-(1,2,5)] serves as an important intermediate for the synthesis of various complex organic molecules. Its unique structure allows for further functionalization and modification, making it a versatile building block for creating novel compounds with potential applications in different industries.
Used in Research and Development:
5-Methyl-3-methanol-1H-pyrazol [1R-(1,2,5)] is also utilized in research and development laboratories for studying the properties and reactivity of pyrazole derivatives. 5-Methyl-3-methanol-1H-pyrazol [1R-(1,2,5)] can provide valuable insights into the structure-activity relationships of pyrazole-based molecules, which can be crucial for the design and development of new drugs and materials.

Upstream product

• 4027-57-0 ethyl 5-methyl-1H-pyrazole-3-carboxylate 
• 52804-46-3 5-[(tetrahydro-2H-pyran-2-yl)oxy]pent-3-yn-2-one 
• 493038-46-3 5-methyl-3-[(tetrahydro-2H-pyran-2-yl)oxy]methylpyrazole 

Downstream Products

• 493038-61-2 3-(diphenylphosphinomethyl)-5-methylpyrazole 

Relevant academic research and scientific papers

Synthesis and characterization of nickel inverse 9-metallacrown-3, palladium-silver, and dinuclear platinum complexes containing pyrazole-functionalized NHC ligands

Three metallacrown nickel complexes [Ni3(μ-OH)(L1) 3](PF6)2 (1, L1 = 3-((N-methylimidazolylidenyl) methyl)-5-methylpyrazolate), [Ni3(μ-OH)(L2)3](PF 6)2 (2, L2 = 3-((N-mesitylimidazolylidenyl)methyl)-5- methylpyrazolate), and [Ni3(μ-OH)(L3)3](PF 6)2 (3, L3 = 3-((N-pyrimidin-2-ylimidazolylidenyl)methyl)- 5-methylpyrazolate) were obtained by the reactions of corresponding silver-NHC complexes with Raney nickel powder at 45 °C. The same reaction at 80 °C afforded [Ni3(L2)4](PF6)2 (4). The carbene-transfer reaction of the silver-carbene complex with [(η3-C3H5)PdCl]2 yielded the heterotrimetallic complex [AgPd2(η3-C 3H5)2(L2)2](PF6) (5), whereas the carbene-transfer reaction with Pt(cod)Cl2 gave [Pt 2(L3)2](PF6)2 (6). All of these complexes have been fully characterized by ESI-MS, NMR spectroscopy, and elemental analysis. The molecular structures of 1-6 were also studied by X-ray diffraction analysis. In 1-3, three nickel centers are bridged together by three pyrazole-NHC ligands and a hydroxide group, forming a 9-metallacrown-3 topology. Complex 4 is paramagnetic, consisting of two square-planar nickel(II) ions and one tetrahedral nickel ion in which three Ni ions are bridged by four pyrazolate units. In the mixed Pd-Ag complex 5, two palladium and one silver centers are bridged by two pyrazole-NHC ligands. Complex 5 showed good catalytic activity in the Sonogashira coupling reaction of aryl bromides and phenylacetylene under mild conditions typically catalyzed by Pd-Cu systems.

New flexible synthesis of pyrazoles with different, functionalized substituents at C3 and C5

Syntheses of pyrazoles featuring a functionalized side chain attached to carbon 3 and varying alkyl and aryl substituents attached to carbon 5 are presented. Installation of R = methyl, isopropyl, tert-butyl, adamantyl, or phenyl groups at C5 is reported

PHARMACOLOGICALLY ACTIVE THIOUREA AND UREA COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.